How This Evidence Evolved
Adrenal Incidentaloma Approach
From incidental finding to evidence-based risk stratification
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Integration into clinical practice guidelines and recommendations
Current standard of care and ongoing research directions
Landmark Trials in This Story
NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma").
Recommended work-up: 1-mg dexamethasone suppression test and plasma-free metanephrines for all; serum potassium and aldosterone/renin ratio if hypertensive; tumors >6 cm usually resected, <4 cm generally monitored, 4-6 cm decided on added criteria
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
Evidence-based recommendations for malignancy risk assessment, hormonal evaluation, surgical criteria, and follow-up
European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors
Updated recommendations with refined imaging criteria, hormonal thresholds, and reduced follow-up requirements
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.